US Appeal Court affirms preliminary injunction against Apotex in PULMICORT RESPULES patent litigation

AstraZeneca is pleased with the ruling and has full confidence in the strength of its intellectual property rights protecting PULMICORT RESPULES and will continue to vigorously defend and enforce its intellectual property.

Patents covering PULMICORT RESPULES expire in 2018 with paediatric exclusivity extending to 2019.

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit:www.astrazeneca.com

CONTACTS:

Media Enquiries:

Neil McCrae +44 207 304 5045  (24 hours) 
Chris Sampson +44 20 7304 5130  (24 hours)
Sarah Lindgreen +44 20 7304 5033  (24 hours)
Abigail Baron +44 20 7304 5034  (24 hours)

Investor Enquiries UK:

Jonathan Hunt  +44 207 304 5087  mob: +44 7775 704032
Karl Hard         +44 207 304 5322  mob: +44 7789 654364

Investor Enquiries US:

Ed Seage            +1 302 886 4065    mob: +1 302 373 1361
Jorgen Winroth    +1 212 579 0506    mob: +1 917 612 4043

02/11/2010